MAHA Went After Seed Oils, Sugar, and Vaccines. Alcohol Got a Pass.

Jillian was 38 when she said the sentence that usually marks the start of someone’s real recovery story: “I got to the point where I said: Holy shit, I can’t stop on my own.” A bottle of vodka went from full in her cabinet to empty in her recycling bin most days. Her marriage didn’t survive it. Her career nearly didn’t either. So she did what the culture tells you to do — she went to AA. And she found the rigid, God-centered messaging didn’t fit her, the abstinence-only framing felt like a wall instead of a door, and — grimly — she watched other members drink after the meetings ended. Her family doctor told her to cut back. Nobody offered her medication. Nobody offered her anything but willpower.

Jillian’s stuck moment is, in miniature, the whole country’s stuck moment on alcohol in 2026 — and it’s the latest chapter in Rize’s policy and funding coverage of a field where the science keeps outrunning the agencies meant to act on it.

The administration that built a health movement around banning what’s in your grocery cart has spent this year making sure nobody has better numbers on what’s in your liquor cabinet.

The list of things MAHA came for, and the one thing it didn’t

The Make America Healthy Again coalition has moved fast and loud in 2026: seed oils, synthetic food dyes, pesticide residues, ultra-processed food additives, even long-settled vaccine science have all drawn public campaigns, agency reviews, and cabinet-level attention. Robert F. Kennedy Jr., now HHS Secretary, has framed nearly all of it as a single project — restoring Americans’ trust in what they consume by naming the things quietly making them sick.

Alcohol — which STAT News’s ongoing “Deadliest Drug” investigation documents kills more Americans each year than infectious disease and opioids combined — never made the list. Not as a campaign, not as a signature initiative, not even as a talking point. If you are the kind of person who has watched a food dye get a press conference while the thing that actually might kill you or someone you love gets silence, you already understand the asymmetry here better than most policy reporters do.

The gap isn’t rhetorical. It shows up in agency-level decisions. This year, the CDC’s dedicated alcohol program was shut down, more than half the staff at a federal substance-use agency was eliminated, and the National Institute on Alcohol Abuse and Alcoholism quietly removed information about moderate-drinking health risks from its own public website in January. Meanwhile, the 2026 Dietary Guidelines for Americans — the federal government’s flagship nutrition document, revised once a decade — dropped the specific numeric drinking limits (two drinks a day for men, one for women) that had stood since 1980, replacing them with the vaguer instruction to “consume less alcohol for better overall health.” The Lancet Gastroenterology & Hepatology called the change “a step backwards” in an editorial reviewing the new guidance.

Somebody in the room used to say no. Not anymore.

STAT’s reporting on why this kept happening points somewhere specific: money, and the people positioned to spend it. Len Lichtenfeld, former deputy chief medical officer at the American Cancer Society, recalled the organization’s alcohol guidance softening over years even as its own epidemiologists pushed for stronger cancer warnings — the same years the ACS was accepting industry money through an annual New York City gala. “It stayed with me, because I knew it was a conflicted situation,” Lichtenfeld said. The ACS eventually moved its own guidance toward abstinence for cancer prevention in 2020, but the years of softer messaging before that shift are exactly the kind of quiet institutional capture that’s easy to miss until someone who was in the room describes it plainly.

That’s the mechanism worth understanding, in plain terms: it’s not that anyone announced a decision to protect the alcohol industry from scrutiny. It’s that the people whose job was to sound the alarm kept finding reasons — funding relationships, institutional caution, a gala that paid the bills — not to. Multiply that dynamic across a cancer charity, a federal agency, and a White House with a health movement that somehow never got around to the deadliest substance on the list, and you get exactly the year alcohol just had: a lot of attention everywhere except where the body count is highest.

It’s that the people whose job was to sound the alarm kept finding reasons — funding relationships, institutional caution, a gala that paid the bills — not to.

Where the abstinence wall came from in the first place

Jillian’s experience with AA’s rigidity isn’t a personal failing or an isolated bad-fit story — it’s the direct legacy of how American alcohol treatment got built in the first place, and understanding that history is most of what explains why alternatives took her, and millions like her, this long to reach.

Alcoholics Anonymous was founded in 1935 by Bill Wilson and Dr. Bob Smith, in the immediate aftermath of Prohibition’s repeal in 1933 — a moment when there were essentially no other treatment pathways for alcoholism in America at all. AA filled a total vacuum, and for the better part of a century, its abstinence-only, twelve-step model became so culturally dominant that it wasn’t really treated as one option among several. It was treated as the treatment, full stop — the thing doctors defaulted to, the thing courts mandated, the thing families were told to expect. Medications like naltrexone and acamprosate existed for decades without meaningfully displacing that default. When a treatment model occupies that much cultural space for that long, the people it doesn’t work for don’t get routed to something else. They get told they haven’t hit bottom yet, or that they aren’t trying hard enough.

That’s the wall Jillian hit ninety years after AA was founded, using almost exactly the same rigid abstinence framing that made sense in a room with no alternatives in 1935 and makes considerably less sense in a room that now has semaglutide trials showing a 41.1% reduction in heavy drinking days and a widening menu of medication and harm-reduction options AA was never built to offer.

What the science says, while the agencies stay quiet

The irony sharpens further because the treatment science genuinely is moving. A randomized, placebo-controlled trial out of Copenhagen University Hospital, published in The Lancet and echoed in an NIH release, found that adding weekly semaglutide to standard cognitive behavioral therapy cut heavy drinking days by 41.1% over 26 weeks, a 13.7-percentage-point improvement over CBT with a placebo. NIAAA director George Koob put the significance in blunt terms: “Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized.” NIDA director Nora Volkow added that “we’re beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality.”

Those are two sitting federal agency directors, on the record, saying the medication side of this crisis is finally producing real answers — the same month their sister agencies were closing programs and scrubbing web pages about the risk side of the same drug. The country isn’t short on people doing the science. It’s short on an administration willing to let the science set the agenda instead of the lobby.

If you’re the person standing where Jillian stood — trying to figure out whether the only path is a rigid one you already know doesn’t fit you — this is what’s actually true right now, whatever the federal websites do or don’t say: medications for alcohol use disorder exist, they work for a meaningful share of people who try them, and your doctor can prescribe them today, guideline debate or not. The agencies can scrub a webpage. They can’t uninvent the trial data. That part’s yours whether Washington campaigns for it or not.